OrthoPediatrics Corp. (NASDAQ:KIDS) Short Interest Up 6.8% in August

OrthoPediatrics Corp. (NASDAQ:KIDS) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 1,250,000 shares, an increase of 6.8% from the July 31st total of 1,170,000 shares. Based on an average daily trading volume, of 85,500 shares, the short-interest ratio is presently 14.6 days. Approximately 8.0% of the shares of the stock are short sold.

Analyst Ratings Changes

KIDS has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $55.00 price target on shares of OrthoPediatrics in a report on Tuesday, August 1st. Truist Financial lowered their price target on shares of OrthoPediatrics from $57.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, August 2nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $60.00 price target on shares of OrthoPediatrics in a report on Tuesday, August 1st. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, OrthoPediatrics presently has an average rating of “Buy” and a consensus target price of $53.60.

Insiders Place Their Bets

In other news, Director Terry D. Schlotterback sold 2,610 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $38.25, for a total value of $99,832.50. Following the completion of the sale, the director now directly owns 15,452 shares in the company, valued at approximately $591,039. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Terry D. Schlotterback sold 2,610 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $38.25, for a total value of $99,832.50. Following the completion of the sale, the director now directly owns 15,452 shares in the company, valued at approximately $591,039. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Fred Hite sold 4,356 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $43.69, for a total transaction of $190,313.64. Following the completion of the sale, the chief financial officer now owns 97,267 shares of the company’s stock, valued at $4,249,595.23. The disclosure for this sale can be found here. Corporate insiders own 32.60% of the company’s stock.

Institutional Trading of OrthoPediatrics

A number of hedge funds and other institutional investors have recently modified their holdings of KIDS. Point72 Hong Kong Ltd purchased a new stake in shares of OrthoPediatrics in the 1st quarter worth about $26,000. Almanack Investment Partners LLC. purchased a new stake in shares of OrthoPediatrics in the 3rd quarter worth about $34,000. FMR LLC grew its position in shares of OrthoPediatrics by 71.7% in the 1st quarter. FMR LLC now owns 874 shares of the company’s stock worth $39,000 after buying an additional 365 shares during the period. State of Wyoming grew its position in OrthoPediatrics by 23.1% during the 4th quarter. State of Wyoming now owns 1,380 shares of the company’s stock valued at $55,000 after purchasing an additional 259 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in OrthoPediatrics during the 1st quarter valued at about $65,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Trading Down 1.1 %

Shares of NASDAQ KIDS opened at $38.22 on Friday. OrthoPediatrics has a 12 month low of $35.63 and a 12 month high of $53.50. The firm has a market capitalization of $892.44 million, a PE ratio of 424.67 and a beta of 0.87. The firm has a fifty day simple moving average of $41.02 and a two-hundred day simple moving average of $43.70.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Monday, July 31st. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $39.56 million for the quarter, compared to the consensus estimate of $39.11 million. OrthoPediatrics had a net margin of 0.73% and a negative return on equity of 5.03%. On average, sell-side analysts predict that OrthoPediatrics will post -0.97 earnings per share for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.